Tumor-Agnostic Classifier & Screener Aids Targeted Drug Development

A tumor-agnostic classifier and screening tool was announced at ESMO Congress 2024 in Barcelona. It was created to make it easier and quicker to develop new drugs that have specific molecular targets, and thus have potential anti-cancer efficacy irrespective of tumor type or location. The ESMO Tumour-Agnostic Classifier and Screener was the result of work by a multidisciplinary team of international experts led by the ESMO Precision Medicine Working Group. At the conference, Benedikt Westphalen, MD, a medical oncologist and molecular biologist who is Head of the Precision Oncology Program at the University of Munich in Germany, talked about the details with Oncology Times correspondent Peter Goodwin.

You can listen to Tumor-Agnostic Classifier & Screener Aids Targeted Drug Development online on Radio and Podcast. Open the player on this page to stream the available audio.

Tumor-Agnostic Classifier & Screener Aids Targeted Drug Development is an episode from Oncology Times - OT Broadcasts from the iPad Archives by Oncology Times.

This episode is 9:21 long.

This episode was published on Jan 10, 2025.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Oncology Times - OT Broadcasts from the iPad Archives when more episodes are available from the podcast feed.